Acelyrin Future Growth
Future criteria checks 0/6
Acelyrin is forecast to grow earnings and revenue by 6.1% and 100.3% per annum respectively. EPS is expected to grow by 13.7% per annum. Return on equity is forecast to be -55.3% in 3 years.
Key information
6.1%
Earnings growth rate
13.7%
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | 100.3% |
| Future return on equity | -55.3% |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -222 | -191 | -153 | 5 |
| 12/31/2025 | N/A | -208 | -185 | -150 | 5 |
| 12/31/2024 | N/A | -252 | -183 | -251 | 5 |
| 9/30/2024 | N/A | -264 | -257 | -256 | N/A |
| 6/30/2024 | N/A | -300 | -217 | -216 | N/A |
| 3/31/2024 | N/A | -240 | -204 | -202 | N/A |
| 12/31/2023 | N/A | -382 | -182 | -170 | N/A |
| 9/30/2023 | N/A | -306 | -126 | -114 | N/A |
| 6/30/2023 | N/A | -237 | -102 | -90 | N/A |
| 3/31/2023 | N/A | -225 | -83 | -72 | N/A |
| 12/31/2022 | N/A | -65 | -62 | -62 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLRN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLRN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLRN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SLRN is forecast to have no revenue next year.
High Growth Revenue: SLRN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SLRN is forecast to be unprofitable in 3 years.